Search Site

Trends banner

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

UAB net profit up by 50% for H1

Total assets increase by 11 percent.

GSK to buy Aiolos Bio

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK's push into its core drugmaking business. (AFP)
  • The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma
  • AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment

London, United Kingdom – British drugmaker GlaxoSmithKline on Tuesday agreed to buy Aiolos Bio for up to $1.4 billion, with focus on an asthma medication still at the testing stage.

The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma.

GSK said in a statement that the drug has the “potential to… reach a broader portion of asthma patients”.

AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment.

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK’s push into its core drugmaking business after the spinoff of consumer healthcare unit Haleon in 2022.

“We have a proud heritage and deep development expertise in respiratory medicines,” GSK’s chief scientific officer Tony Wood said in the statement.

“Adding AIO-001, a potentially best-in-class medicine… could expand the reach of our current respiratory biologics portfolio.”